Pulmatix to provide consultancy and testing services to the respiratory R&D sector

011656965_staff and researchers checking equipment in biotech industry.jpeg

RespiTech Members Celebrate Launch of New Respiratory Consultancy and Contract Testing Services Company, Housed at the WIMR

Pulmatix is a dynamic new company offering consultancy and testing services to the pharmaceutical sector.  We can provide a range of services ranging from molecular pharmacological studies of drug and excipient interactions at the lung interface to advanced physical characterisation, device development and aerosol evaluation.

Paul M Young and Judy Black, two of the Directors of Pulmatix commented:

"We are in a unique position to offer a range of services, from molecular pharmacological studies of drug and excipient interactions at the lung interface, to advanced physical characterisation, device development and aerosol evaluation. Our key management team has extensive experience in respiratory pharmacology, physicochemical characterisation and aerosol formulation."

Pulmatix has state-of-the-art cellular biology and aerosol testing laboratories and a scientific team with the expertise to match. Whether a company requirement is to solve a production problem for a current formulation, study the effectiveness of an API after deposition in the lung or wish to re-formulate an existing product or develop a new one, Pulmatix can help.

For more information visit www.pulmatix.com